367 related articles for article (PubMed ID: 21811962)
1. Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.
Polyzos SA; Anastasilakis AD; Makras P; Terpos E
Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):519-24. PubMed ID: 21811962
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
[TBL] [Abstract][Full Text] [Related]
3. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
4. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
Polyzos SA; Anastasilakis AD; Litsas I; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
J Bone Miner Metab; 2010 Nov; 28(6):706-12. PubMed ID: 20533067
[TBL] [Abstract][Full Text] [Related]
5. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
Siris ES; Lyles KW; Singer FR; Meunier PJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
[TBL] [Abstract][Full Text] [Related]
6. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
Whitson HE; Lobaugh B; Lyles KW
Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
[TBL] [Abstract][Full Text] [Related]
7. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
[TBL] [Abstract][Full Text] [Related]
8. Preventive Role of Vitamin D Supplementation for Acute Phase Reaction after Bisphosphonate Infusion in Paget's Disease.
Merlotti D; Rendina D; Muscariello R; Picchioni T; Alessandri M; De Filippo G; Materozzi M; Bianciardi S; Franci MB; Lucani B; Cenci S; Strazzullo P; Nuti R; Gennari L
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31634910
[TBL] [Abstract][Full Text] [Related]
9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
10. Current treatment approaches for Paget's Disease of Bone.
Brandi ML
Discov Med; 2010 Sep; 10(52):209-12. PubMed ID: 20875342
[TBL] [Abstract][Full Text] [Related]
11. Osteomalacia in a patient with Paget's bone disease treated with long-term etidronate.
Hoppé E; Masson C; Laffitte A; Chappard D; Audran M
Morphologie; 2012 Aug; 96(313):40-3. PubMed ID: 23022200
[TBL] [Abstract][Full Text] [Related]
12. Multiple fractures in a woman receiving 24 years of etidronate treatment for Paget's disease.
Labinson P; Taxel P
Conn Med; 2007 May; 71(5):269-73. PubMed ID: 17526382
[No Abstract] [Full Text] [Related]
13. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
15. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
[TBL] [Abstract][Full Text] [Related]
16. Management of Paget's disease of bone.
Langston AL; Ralston SH
Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of resistant Paget's disease of bone with pamidronate.
Mallette LE
Arch Intern Med; 1989 Dec; 149(12):2765-7. PubMed ID: 2596945
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological therapy of Paget's and other metabolic bone diseases.
Hosking D
Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
[TBL] [Abstract][Full Text] [Related]
19. A tale of three diseases of the bone.
Kannan S; Mahadevan S; Sathya A; Sriram U
Singapore Med J; 2008 Oct; 49(10):e263-5. PubMed ID: 18946593
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates.
Wang-Gillam A; Miles DA; Hutchins LF
Oncologist; 2008 Jul; 13(7):821-7. PubMed ID: 18614589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
